Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOW-OGESTREL-21 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive. Suppresses gonadotropin release (FSH and LH) via estrogen (ethinyl estradiol) and progestin (norgestrel), inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrium.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily for 21 days, followed by 7 pill-free days.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Norgestrel: 18-28 hours; ethinyl estradiol: 13-27 hours. Steady-state achieved after 5-7 days.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Hepatic via CYP3A4 isoenzymes (ethinyl estradiol and norgestrel undergo hydroxylation and conjugation). Enterohepatic circulation.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Ethinyl estradiol and norgestrel are excreted primarily as glucuronide and sulfate conjugates in urine (50-60%) and feces (30-40%).
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Norgestrel: 93-95% (albumin, SHBG); ethinyl estradiol: 97-98% (albumin).
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Norgestrel: 3.5-4.5 L/kg; ethinyl estradiol: 2.5-3.5 L/kg; indicates extensive tissue distribution.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: norgestrel >90%; ethinyl estradiol 40-50% (first-pass metabolism).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dosage adjustment required for mild to moderate renal impairment. Use is contraindicated in severe renal impairment or acute renal failure due to potential fluid retention.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Do not use.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use before menarche. For postmenarchal adolescents, use same dosing as adults: one tablet daily for 21 days, then 7 days off.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for postmenopausal women. No specific geriatric dosing; contraindicated in women over 35 who smoke, and generally avoided in older women due to increased cardiovascular risk.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, thromboembolism, stroke). Risk increases with age (>35 years) and smoking severity. Women over 35 who smoke should not use this drug.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thromboembolic disorders (venous and arterial),Cerebrovascular disease,Myocardial infarction,Hypertension,Hepatic adenoma or carcinoma,Gallbladder disease,Carbohydrate/lipid metabolism effects,Ocular changes (e.g., retinal thrombosis),Headache/migraine exacerbation,Uterine bleeding irregularities,Fetal development (discontinue if pregnancy suspected),Depression,Contact lens intolerance,Fluid retention,Breast cancer risk (ongoing surveillance),Hereditary angioedema
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Known or suspected pregnancy,Current or history of thrombophlebitis or thromboembolic disorders,Current or history of cerebrovascular or coronary artery disease,Breast cancer or other estrogen-sensitive neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known liver impairment,Major surgery with prolonged immobilization,Diabetes mellitus with vascular involvement,Uncontrolled hypertension,Hypertriglyceridemia,Smoking >15 cigarettes/day and age ≥35,Migraine with focal aura at any age
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No significant food interactions. Grapefruit juice may slightly increase estrogen exposure but does not require avoidance. Alcohol does not impair contraceptive efficacy but may increase risk of nausea or missed doses.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Pregnancy category X. Contraindicated in pregnancy. Fetal risk includes cardiovascular anomalies, neural tube defects, and limb reduction defects if exposed during first trimester. Second and third trimester exposure may cause masculinization of female fetuses due to progestin component.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Small amounts of ethinyl estradiol and norgestrel are excreted in human milk. M/P ratio not established. May reduce milk production and composition. Use is generally not recommended during breastfeeding; alternative contraception advised.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Contraindicated in pregnancy; no dose adjustments indicated as drug should not be used. Pharmacokinetic changes in pregnancy (e.g., increased clearance) are not relevant due to contraindication.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
LOW-OGESTREL-21 is a low-dose estrogen-progestin combination oral contraceptive. Its effectiveness may be reduced by concomitant enzyme-inducing drugs (e.g., rifampin, carbamazepine, phenytoin, St. John's wort). Breakthrough bleeding and spotting are more common with low-dose formulations. Contraception is not reliable if two or more active pills are missed; backup contraception is required. Initiation on the first day of menstrual bleeding eliminates need for backup contraception. Advise patients to take pill at same time daily to maintain consistent hormone levels.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time, even if you have spotting or bleeding between periods.,If you miss one pill, take it as soon as you remember and continue the next pill at the usual time; no backup is needed.,If you miss two consecutive active pills, take two pills daily for two days, then resume one daily; use backup contraception for 7 days.,Possible side effects include nausea, headache, breast tenderness, and irregular bleeding; these often improve after 3 cycles.,Smoking while using this pill increases risk of serious cardiovascular events; do not smoke if over 35 years old.,Use a backup method (e.g., condoms) until you have taken 7 consecutive active pills if starting for the first time after day 5 of menstrual cycle.,Store pills at room temperature away from moisture.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOW-OGESTREL-21 vs ALYACEN 7/7/7, answered by our medical review team.
LOW-OGESTREL-21 is a Oral Contraceptive that works by Combination oral contraceptive. Suppresses gonadotropin release (FSH and LH) via estrogen (ethinyl estradiol) and progestin (norgestrel), inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrium.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOW-OGESTREL-21 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOW-OGESTREL-21 is: One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily for 21 days, followed by 7 pill-free days.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOW-OGESTREL-21 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOW-OGESTREL-21 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy. Fetal risk includes cardiovascular anomalies, neural tube defects, and limb reduction defects if exposed during first trimester.. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.